Title: Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
Journal: Journal of medicinal chemistry 20140925
Title: [Diphenylhydantoin-beta-adrenolytic combinations and digitalis poisoning].
Journal: Coeur et medecine interne 19750101
Title: Jia H, et al. Discovery of (S)-1-(1-(Imidazo,2-apyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-,2,3triazolo,5-bpyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57(18):7577-89.
Title: Gavine PR, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015 Jan;9(1):323-33.
